Marketing: Page 49
-
Alexion bolsters Soliris patent defense
Three new patent grants, including one for composition of matter, should help keep competition to the rare disease drug at bay.
By Jacob Bell • Aug. 16, 2017 -
South Carolina slaps Purdue with opioid lawsuit
As the U.S. grapples with an opioid overdose epidemic, the Palmetto State joins the recent legal scrutiny of painkiller drug manufacturers.
By Suzanne Elvidge • Aug. 16, 2017 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.
By BioPharma Dive staff -
Drug pricing — what you need to know
Controversy over rising drug prices has put industry on the defensive in recent years. In this Spotlight, BioPharma Dive explores the trends fueling the debate, as well as emerging responses.
By Lisa LaMotta • Aug. 15, 2017 -
Could indication-based pricing really work?
Such a system rattles patients, but may be a model the industry can get behind.
By Malorye A. Branca • Aug. 14, 2017 -
Deep Dive
5 Trends influencing drug pricing
When pricing medications, drugmakers now weigh consumer outrage, negotiating power and calls for transparency.
By Jacob Bell • Aug. 14, 2017 -
The secret recipe behind the launch price of a drug
Finding the right ingredients to set the perfect drug price is a little bit of art and a whole lot of science.
By Lisa LaMotta • Aug. 14, 2017 -
Opioid drugmakers may have to slash production under new DEA proposal
The agency is mulling a 20% reduction in the manufacturing of the Schedule II drugs for 2018.
By Jacob Bell • Aug. 9, 2017 -
Payer coverage boosts Radius' Tymlos
A decision by Express Scripts to cover Tymlos preferentially in place of Eli Lilly's Forteo next year should give the biotech a leg up.
By Ned Pagliarulo • Aug. 4, 2017 -
Dynavax dips as its hep B drug faces another setback
The FDA's request for more information on a planned, post-marketing study of Heplisav-B is pushing back an approval decision.
By Jacob Bell • Aug. 4, 2017 -
As Roche wades biosimilar waters, more competitors circle Herceptin
The FDA accepted two additional filings for versions of the breast cancer biologic earlier this week.
By Jacob Bell • Aug. 2, 2017 -
CVS Health removes 17 drugs from formulary, adds outcomes-based program
The pharmacy benefit manager put out its 2018 list, removing Eli Lilly's Jardiance while bringing back in Pfizer's Xtandi and J&J's Invokana.
By Lisa LaMotta • Aug. 2, 2017 -
Kite first to file for CAR-T approval in Europe
In the U.S., however, Novartis looks set to secure the first approval for a CAR-T therapy, winning the unanimous support of a FDA advisory panel in July.
By Suzanne Elvidge • Aug. 2, 2017 -
Idhifa approval furthers Celgene's diversification goals
Revlimid continues to make up 60% of Celgene's revenues, but a new product for acute myeloid leukemia could help spread the wealth.
By Jacob Bell • Aug. 1, 2017 -
Puma's early Nerlynx launch raises doubts of a takeover
The company's decision to commercialize its breast cancer drug dampens the prospect of a near-term acquisition, according to a recent analyst report.
By Jacob Bell • Aug. 1, 2017 -
Sponsored by MicroMass Communications, Inc.
Instead of being patient centered, try being patient informed
To be successful, a brand must go beyond persuasive product messages and work to support the whole patient, not just their clinical needs.
By Meredith Terry, Senior Behaviorist • Aug. 1, 2017 -
Vertex wins new Kalydeco approval, ups sales forecast
A label expansion will increase the patient population treatable by Vertex's older cystic fibrosis drug, strengthening the biotech's position.
By Ned Pagliarulo • Aug. 1, 2017 -
Express Scripts shuts out 64 branded drugs from 2018 formulary
Among the drugs excluded from the PBM's preferred list were Amgen's Neupogen, Eli Lilly's Forteo and Synergy Pharmaceuticals' newly approved Trulance.
By Ned Pagliarulo • July 31, 2017 -
AbbVie confident in strategy as Humira mints money
Despite growing competitive threats in immunology, AbbVie believes it can maintain its leadership position.
By Ned Pagliarulo • July 28, 2017 -
Tesaro lands licensing, supply agreements for Zejula
Two separate deals have Takeda handing over $100 million upfront for rights to the cancer med and STA Pharmaceutical providing the materials to make it.
By Jacob Bell • July 27, 2017 -
FDA
GSK gets go-ahead for new Benlysta formulation
Approval brings the first self-injectable treatment for the most common form of lupus to market, according to the British drugmaker.
By Jacob Bell • July 26, 2017 -
Merck undercuts Pfizer on Remicade biosimilar price
Looking to steal share, Merck priced its biosimilar version at a 35% discount to Remicade's list price, upping the threat faced by J&J's blockbuster biologic.
By Ned Pagliarulo • July 26, 2017 -
AbbVie faces $150M in damages in AndroGel trial
The Illinois drugmaker will have to pay up for fraudulent representation of the testosterone treatment and faces further damages as class action suits progress.
By Suzanne Elvidge • July 26, 2017 -
Celgene pays $280M to make fraud allegations go away
The big biotech admitted no wrongdoing, but settled the lawsuit in hopes of putting the off-label promotion matter in the past and off its balance sheet.
By Jacob Bell • July 26, 2017 -
Spinraza launch set for blockbuster trajectory
Biogen surprised the markets with stronger-than-expected earnings for its rare disease drug. But can those sales last?
By Lisa LaMotta • July 25, 2017 -
5 orphan drugs receive EMA thumbs-up
Pfizer and Merck KGaA's Bavencio and Novartis' Rydapt were among the 11 drugs recommended for approval during the Committee for Medicinal Products for Human Use's July meeting.
By Jacob Bell • July 21, 2017
Previous
